Kathy Zhang

发表

Immunogenicity of panitumumab in combination chemotherapy clinical trials

J. Pérez-Ruixo, N. Chirmule, Bing‐Bing Yang, 2011, BMC clinical pharmacology.

Evaluation of Individual Codon 12 and 13 Mutant (MT) KRAS Alleles as Prognostic and Predictive Biomarkers of Response to Panitumumab (pmab) in Patients with Metastatic Colorectal Cancer (mCRC)

J. Douillard, R. Williams, S. Siena, 2011 .

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.

Marc Peeters, Tae Won Kim, P. Ruff, 2014, The Lancet. Oncology.

O-0011FREQUENCY OF S492R MUTATIONS IN THE EPIDERMAL GROWTH FACTOR RECEPTOR: ANALYSIS OF PLASMA DNA FROM METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH PANITUMUMAB OR CETUXIMAB MONOTHERAPY

Tae Won Kim, P. Ruff, M. Boedigheimer, 2014 .

Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study.

B. Monk, B. Karlan, A. Oza, 2015 .

Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.

E. Van Cutsem, J. Douillard, R. Williams, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).

Tae Won Kim, P. Ruff, M. Boedigheimer, 2015 .

An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.

David A. Smith, M. Yassine, A. Cohn, 2011, Clinical colorectal cancer.

Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours

M. Millward, L. Mileshkin, G. Kichenadasse, 2021, British Journal of Cancer.

A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Daniel J. Freeman, J. Crawford, D. Prager, 2013, Journal of Thoracic Oncology.

Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab).

E. Van Cutsem, J. Douillard, R. Williams, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects

J. Ibrahim, D. Zeng, Qingxia Chen, 2017, Journal of biopharmaceutical statistics.

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.

Tae Won Kim, P. Ruff, M. Peeters, 2014, The Lancet. Oncology.